Press Releases Entrada Therapeutics, Inc.

Equities

TRDA

US29384C1080

Market Closed - Nasdaq Other stock markets 01:30:00 15/05/2024 am IST			5-day change	1st Jan Change
14.19 ^USD	+1.00%		+2.23%	-5.96%

07/05	Entrada Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
13/03	Entrada Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Entrada Therapeutics : Corporate Presentation	07/05	PU
Entrada Therapeutics Reports First Quarter 2024 Financial Results	07/05	GL
Entrada Therapeutics : Corporate Presentation	13/03	PU
Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results	13/03	GL
Entrada Therapeutics : Corporate Presentation	04/03	PU
Entrada Therapeutics to Present at Upcoming Investor Conferences	07/02	GL
Entrada Therapeutics Promotes Nathan J. Dowden to President	03/01	GL
Pomerantz Law Firm Investigates Claims On Entrada Therapeutics, Inc. - TRDA	19/12	PR
Pomerantz Law Firm Investigates Claims On Entrada Therapeutics, Inc. - TRDA	30/11	PR
Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy	22/11	GL
Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy	22/11	AQ
Entrada Therapeutics Reports Third Quarter 2023 Financial Results	07/11	GL
Entrada Therapeutics to Present at Upcoming Investor Conferences	12/23/12	GL
Entrada Therapeutics to Present at Upcoming Investor Conferences	12/23/12	AQ
Entrada Therapeutics : Corporate Presentation	21/23/21	PU
Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy	21/23/21	GL
Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy	21/23/21	AQ
Entrada Therapeutics Awards Funding to Non-Profit Organizations Advancing Diversity, Equity, Inclusion and Accessibility within the Duchenne Muscular Dystrophy Community	07/23/07	GL
Entrada Therapeutics : Corporate Presentation	01/23/01	PU
Entrada Therapeutics to Present at Upcoming Investor Conferences	29/23/29	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Entrada Therapeutics, Inc.

Equities

TRDA

US29384C1080

Press Releases

Filters